secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2026-06-23T12:00:06+00:00
Accession:  0001193125-26-278533
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom completes enrollment in Phase 2 EoE trial; topline data expected Q4 2026
--------------------------------------------------------------------------------

- Enrolled 95 adults at 41 US sites in pHalcon-EoE-201 Phase 2 trial of VOQUEZNA for eosinophilic esophagitis.
- Patients randomized 1:1 to VOQUEZNA 20 mg or placebo once daily for 12 weeks; optional open-label extension.
- Topline results anticipated in Q4 2026; positive data could lead to FDA discussions on pediatric exclusivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/0001193125-26-278533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-278533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer